E-ISSN 2148-5607
RELATED ARTICLES
Editorial
Is there any relationship between Behçet's disease and hepatit C virus?
(Turk J Gastroenterol 1998; 9: 10-13)
Hepatitis C infection in non-Hodgkin's lymphoma
(Turk J Gastroenterol 1998; 9: 73-75)
Hepatitis C virus and deep abdominal lymphadenopathy
(Turk J Gastroenterol 1998; 9: 91-94)
The quality of life in hemodialysis patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2009; 20: 243-246)
DOI: 10.4318/tjg.2009.0020
Prevelance and genotyping of hepatitis C virus RNA in Turkish patinets with non-A, non-B liver disease
(Turk J Gastroenterol 1998; 9: 208-212)
Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C
(Turk J Gastroenterol 2007; 18: 268-271)
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: One year follow-up after 48 weeks of treatment
(Turk J Gastroenterol 2006; 17: 35-39)
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients
(Turk J Gastroenterol 2006; 17: 94-98)
Assessment of bone metabolism and mineral density in chronic viral hepatitis
(Turk J Gastroenterol 2006; 17: 260-266)
Hepatitis B and C virus in West-Central Turkey: Seroprevalence in healthy individuals admitted to a university hospital for routine health checks
(Turk J Gastroenterol 2006; 17: 267-272)
Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing ornon-responding to previous interferon
(Turk J Gastroenterol 2000; 11: 191-195)
Lichen planus and HCV infection in Turkish patients
(Turk J Gastroenterol 2004; 15: 133-136)
Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C
(Turk J Gastroenterol 2001; 12: 89-94)
Chronic hepatitis C with mixed cryoglubulinemia: A cade report
(Turk J Gastroenterol 1996; 7: 254-256)
Clinicopathologic features and risk factors for hepatocellular carcinoma: Results from a single center in southern Turkey
(Turk J Gastroenterol 2003; 14: 85-90)
Type 1 gastric carcinoid tumor: another extrahepatic manifestation of hepatitis C virus infection?
(Turk J Gastroenterol 2003; 14: 194-196)
Autoantibodies in chronic viral hepatitis and autoimmune hepatitis
(Turk J Gastroenterol 1997; 8: 381-384)
Importance of second and third generation ELISA test in detection of HVC antibody
(Turk J Gastroenterol 1997; 8: 144-147)
Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: A population-based study
(Turk J Gastroenterol 2009; 20: 27-30)
Transmission routes of chronic hepatitis C and their relation to HCV genotypes
(Turk J Gastroenterol 2010; 21: 396-400)
DOI: 10.4318/tjg.2010.0126
HCV genotypes in HCV related chronic hepatitis in Southeast Anatolia
(Turk J Gastroenterol 1999; 10: 249-252)
Review
Show Me Echo – Hepatitis C: A telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries
(Turk J Gastroenterol 2015; 26: 447-449)
DOI: 10.5152/tjg.2015.159000
New modalities in the treatment of HCV in pre and post - transplantation setting
(Turk J Gastroenterol 2015; 26: 204-213)
DOI: 10.5152/tjg.2015.0204
Original Article
Gallstones in liver transplant recipients: A single-center study in China
(Turk J Gastroenterol 2015; 26: 429-434)
DOI: 10.5152/tjg.2014.6344
The impact of hepatitis C virus infection on long-term outcome in renal transplant patients
(Turk J Gastroenterol 2011; 22: 165-170)
DOI: 10.4318/tjg.2011.0236
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2011; 22: 279-285)
DOI: 10.4318/tjg.2011.0213
Serum complement C4 in chronic hepatitis C: Correlation with histopathologic findings and disease activity
(Turk J Gastroenterol 2012; 23: 33-37)
DOI: 10.4318/tjg.2012.0310
Possible transmission risks and genotype distribution of hepatitis C virus infection in Western Turkey
(Turk J Gastroenterol 2013; 24: 349-355)
DOI: 10.4318/tjg.2013.0518
Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients
(Turk J Gastroenterol 2012; 23: 538-545)
DOI: 10.4318/tjg.2012.0358
Risk factors for higher anti-HCV positivity in a border city in southern Turkey with unique population characteristics
(Turk J Gastroenterol 2012; 23: 574-579)
DOI: 10.4318/tjg.2012.0554
Fatty liver disease might increase the risk of abdominal operation in patients with fatty liver and the prevalence of cancer in first-degree relatives
(Turk J Gastroenterol 2014; 25: 138-141)
DOI: 10.5152/tjg.2014.7674
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
(Turk J Gastroenterol 2016; 27: 55-61)
DOI: 10.5152/tjg.2015.150280
Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5’UTR regions in genotyping efficiency
(Turk J Gastroenterol 2014; 25: 405-410)
DOI: 10.5152/tjg.2014.7083
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2016; 27: 156-164)
DOI: 10.5152/tjg.2015.150449
The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey
(Turk J Gastroenterol 2014; 25: 546-552)
DOI: 10.5152/tjg.2014.7829
Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
(Turk J Gastroenterol 2016; 27: 165-172)
DOI: 10.5152/tjg.2016.150300
Evaluation of fluvastatin in combination with the standard of care therapy (PEG-IFN/Ribavirin) in Egyptian patients with hepatitis C virus
(Turk J Gastroenterol 2015; 26: 511-516)
DOI: 10.5152/tjg.2015.15806
Effects of mannose-binding lectin and mannose-binding lectin polymorphisms on treatment response in patients with chronic hepatitis C
(Turk J Gastroenterol 2014; 25: 702-706)
DOI: 10.5152/tjg.2014.6583
Liver - Original Article
Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey
(Turk J Gastroenterol 2019; 30: 260-265)
DOI: 10.5152/tjg.2018.17634
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
(Turk J Gastroenterol 2019; 30: 331-335)
DOI: 10.5152/tjg.2018.18269
Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores
(Turk J Gastroenterol 2018; 29: 308-315)
DOI: 10.5152/tjg.2018.17631
Insulin/high-density lipoprotein cholesterol ratio: A newly-discovered predictor of esophageal varices in patients with hepatitis C virus-related cirrhosis in the absence of diabetes mellitus
(Turk J Gastroenterol 2019; 30: 155-162)
DOI: 10.5152/tjg.2018.18237
Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
(Turk J Gastroenterol 2017; 28: 283-288)
DOI: 10.5152/tjg.2017.16640
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol 2018; 29: 464-472)
DOI: 10.5152/tjg.2018.16597
Poster
Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
(Turk J Gastroenterol 2019; 30: 10-15)
DOI: 10.5152/tjg.2019.07
From cirrhosis to hepatocellular carcinoma: An investigation into hepatitis C viral oncogenesis using meta-analysis
(Turk J Gastroenterol 2019; 30: 26-28)
DOI: 10.5152/tjg.2019.15
Successfully treatment of chronic hepatitis C with direct-acting antiviral agents: a single center experience
(Turk J Gastroenterol 2019; 30: 34-34)
DOI: 10.5152/tjg.2019.20
Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2019; 30: 43-45)
DOI: 10.5152/tjg.2019.28
Direct-acting antiviral drugs used ın the treatment of HCV Increase cholesterol levels
(Turk J Gastroenterol 2019; 30: 69-69)
DOI: 10.5152/tjg.2019.46
Effect of sofosbuvir on QT interval and other electrocardiography (ECG) findings in patients with HCV related decompase cirrhosis
(Turk J Gastroenterol 2019; 30: 76-76)
DOI: 10.5152/tjg.2019.51
Investigation of the factors affecting the response of treatment ın patients treated with oral direct acting antiviral agents
(Turk J Gastroenterol 2019; 30: 79-80)
DOI: 10.5152/tjg.2019.53
Awareness of hepatitis C
(Turk J Gastroenterol 2019; 30: 85-85)
DOI: 10.5152/tjg.2019.56
Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 04.07.2019